Upcoming Webinar Series: Expand your HIV Toolkit with CA Statewide Trainings on Extended-Release Injectable Suspensions for HIV Treatment and Prevention (January 20, 2022)

Purpose

The purpose of this four-part series is to equip California clinicians, pharmacists, and members of the healthcare team with an in-depth understanding of Cabotegravir/ Rilpivirine, the first FDA-approved long-acting injectable for patients with HIV. Attendees will gain real-world patient and provider perspectives; a guide to patient eligibility, clinical considerations, insurance coverage; and insight into cultural consideration. Participants will also have access to a comprehensive toolkit with FAQs, protocols, and other resources to strengthen confidence when implementing treatment.

Session Breakdown

• Session 1: Medication Management 101: a foundation in prescribing practices, and clinic implementation experiences
• Session 2: Treatment in the Real World: join a patient-provider panel discussion and get answers to your own questions and FAQs
• Session 3: Injectables for PrEP: foundations in clinical practices and lessons learned from other types of injectables for prevention
• Session 4: The Future of Injectables: discuss the possibilities now that prevention and care are possible

Learning Objectives

By the end of the four-part series, attendees will be able to:

• Describe the steps and consideration for operationalizing the roll out of the treatment
• Discuss patient, provider, healthcare administration experiences with the long-acting injectable and best practices for implementation
• Summarize the implementation considerations for long-acting injectables for PrEP
• Explore how to implement injectables with the lens of cultural humility and foster medical trust
• Access a toolkit with checklists, protocols patient and provider FAQs

Click here to register for all four sessions now!

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

 This project is supported by the Health Resources and Services Administration(HRSA) of the U.S. Department of Health and Human Services(HHS)as part of an award totaling $3,278,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or theU.S.Government.